Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Broad phase II study of vindesine

M Valdivieso, A Y Bedikian, G P Bodey

    Cancer Treatment Reports
    |September 1, 1981
    PubMed
    Summary

    Vindesine shows promise in treating advanced cancers, including colorectal cancer and melanoma, with manageable side effects. This study supports further research into vindesine

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Phase II trial of imatinib mesylate in patients with metastatic melanoma.

    British journal of cancer·2008
    Same author

    Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver).

    The Lancet. Oncology·2002
    Same author

    Clinical research today and tomorrow.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2002
    Same author

    Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.

    Leukemia & lymphoma·2001
    Same author

    "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.

    Leukemia & lymphoma·2001

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Vindesine, a vinca alkaloid, is an antineoplastic agent.
    • Previous chemotherapy, including vincristine, was common in the patient population.

    Purpose of the Study:

    • To evaluate the efficacy and safety of vindesine in adults with advanced malignancies.
    • To determine if prior vinca alkaloid therapy impacts vindesine's effectiveness.

    Main Methods:

    • A broad phase II study involving 79 adult patients with advanced solid tumors.
    • Vindesine administered intravenously at 3-4 mg/m2 every 2 weeks, adjusted for tolerance.
    • Patients with colorectal cancer, esophageal squamous cell cancer, malignant melanoma, and lymphoma were included.

    Main Results:

    • Objective tumor regressions observed in 8/36 patients with colorectal cancer (1 CR, 1 PR, 6 minor responses).
    • Partial responses (PR) seen in one patient each with esophageal squamous cell cancer, malignant melanoma, and lymphoma.
    • Five of 11 responding patients had prior vincristine treatment.
    • Toxic effects were manageable.

    Conclusions:

    • Vindesine demonstrated objective tumor regressions in various advanced malignancies.
    • The study supports further disease-oriented phase II evaluations of vindesine.
    • Vindesine's efficacy is notable even in patients with prior exposure to other vinca alkaloids.

    Related Experiment Videos